ACHILLION PHARMACEUTICALS INC Form 3 July 06, 2015 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

#### OMB APPROVAL

OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> JOHNSON & JOHNSON			2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name <b>and</b> Ticker or Trading Symbol ACHILLION PHARMACEUTICALS INC [ACHN]				
(Last)	(First)	(Middle)	07/01/2015	4. Relationship of Reporting Person(s) to Issuer			5. If Amendment, Date Original Filed(Month/Day/Year)	
ONE JOHNSON & JOHNSON PLAZA				(Check	all applicable)			
NEW BRUNSWIC	(Street) K, NJÂ	08933		Director Officer (give title below	Other	ſ	<ul> <li>6. Individual or Joint/Group</li> <li>Filing(Check Applicable Line)</li> <li> Form filed by One Reporting</li> <li>Person</li> <li>_X_ Form filed by More than One</li> <li>Reporting Person</li> </ul>	
(City)	(State)	(Zip)	Table I - I	Table I - Non-Derivative Securities Beneficially Owned				
1.Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)		4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Common Sto	ck		18,367,34	6	Ι	•	ohnson & Johnson vation - JJDC, Inc. $(1)$	
Reminder: Repo owned directly o		ate line for ea	ch class of securities benefic	cially S	EC 1473 (7-02	.)		
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.								

#### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial Ownership
	(Month/Day/Year)	Derivative Security	or Exercise	Form of	(Instr. 5)
		(Instr. 4)	Price of	Derivative	
			Derivative	Security:	

### Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 3

Date	Expiration	Title	Amount or	Security	Direct (D)
Exercisable	Date		Number of		or Indirect
			Shares		(I)
					(Instr. 5)

# **Reporting Owners**

<b>Reporting Owner Name / Address</b>		Relationsl			
	Director	10% Owner	Officer	Other	
JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933	Â	ÂX	Â	Â	
Johnson & Johnson Innovation - JJDC, Inc. ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933	Â	ÂX	Â	Â	
Signatures					
Douglas Chia, Secretary of Johnson & Johnson					
**Signature of Reporting Person					
Steven M. Rosenberg, Secretary of Johnson & Johnson Innovation - JJDC, Inc.					
<u>**</u> Signature of Reporting Pe	Date				
Evaluation of Doononooo					

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.